We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Changes Course on Novartis Treatment for MS
The UK’s National Institute of Health and Care Excellence (NICE) has recommended Novartis’ Mayzent (siponimod) for treating secondary progressive multiple sclerosis (MS) after previously declining to support the drug.